Logo image of NUVB

NUVATION BIO INC (NUVB) Stock Fundamental Analysis

NYSE:NUVB - New York Stock Exchange, Inc. - US67080N1019 - Common Stock - Currency: USD

2.21  -0.06 (-2.64%)

After market: 2.21 0 (0%)

Fundamental Rating

2

Taking everything into account, NUVB scores 2 out of 10 in our fundamental rating. NUVB was compared to 194 industry peers in the Pharmaceuticals industry. The financial health of NUVB is average, but there are quite some concerns on its profitability. NUVB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NUVB has reported negative net income.
NUVB had a negative operating cash flow in the past year.
NUVB had negative earnings in each of the past 5 years.
In the past 5 years NUVB always reported negative operating cash flow.
NUVB Yearly Net Income VS EBIT VS OCF VS FCFNUVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of NUVB (-93.12%) is worse than 77.84% of its industry peers.
NUVB has a Return On Equity of -105.88%. This is in the lower half of the industry: NUVB underperforms 60.54% of its industry peers.
Industry RankSector Rank
ROA -93.12%
ROE -105.88%
ROIC N/A
ROA(3y)-12.96%
ROA(5y)-19.12%
ROE(3y)-13.36%
ROE(5y)-19.69%
ROIC(3y)N/A
ROIC(5y)N/A
NUVB Yearly ROA, ROE, ROICNUVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 200 -200 400

1.3 Margins

NUVB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NUVB Yearly Profit, Operating, Gross MarginsNUVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

NUVB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NUVB has been increased compared to 5 years ago.
NUVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NUVB Yearly Shares OutstandingNUVB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M
NUVB Yearly Total Debt VS Total AssetsNUVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 4.66 indicates that NUVB is not in any danger for bankruptcy at the moment.
NUVB has a Altman-Z score of 4.66. This is in the better half of the industry: NUVB outperforms 79.46% of its industry peers.
NUVB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
NUVB has a Debt to Equity ratio of 0.02. This is comparable to the rest of the industry: NUVB outperforms 54.05% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 4.66
ROIC/WACCN/A
WACCN/A
NUVB Yearly LT Debt VS Equity VS FCFNUVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 9.57 indicates that NUVB has no problem at all paying its short term obligations.
The Current ratio of NUVB (9.57) is better than 80.54% of its industry peers.
A Quick Ratio of 9.57 indicates that NUVB has no problem at all paying its short term obligations.
NUVB's Quick ratio of 9.57 is amongst the best of the industry. NUVB outperforms 80.54% of its industry peers.
Industry RankSector Rank
Current Ratio 9.57
Quick Ratio 9.57
NUVB Yearly Current Assets VS Current LiabilitesNUVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

NUVB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13.16%.
EPS 1Y (TTM)-13.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 16.54% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-547.4%
EPS Next 2Y-36.16%
EPS Next 3Y-14.85%
EPS Next 5Y16.54%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NUVB Yearly Revenue VS EstimatesNUVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
NUVB Yearly EPS VS EstimatesNUVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NUVB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NUVB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NUVB Price Earnings VS Forward Price EarningsNUVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NUVB Per share dataNUVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A cheap valuation may be justified as NUVB's earnings are expected to decrease with -14.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-36.16%
EPS Next 3Y-14.85%

More info and screens

0

5. Dividend

5.1 Amount

NUVB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUVATION BIO INC

NYSE:NUVB (2/21/2025, 8:04:01 PM)

After market: 2.21 0 (0%)

2.21

-0.06 (-2.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners59.63%
Inst Owner Change-96.25%
Ins Owners25.33%
Ins Owner Change1.84%
Market Cap743.82M
Analysts85.45
Price Target8.67 (292.31%)
Short Float %10.32%
Short Ratio10.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-82.25%
Min EPS beat(2)-151.38%
Max EPS beat(2)-13.12%
EPS beat(4)2
Avg EPS beat(4)-23.06%
Min EPS beat(4)-151.38%
Max EPS beat(4)43.89%
EPS beat(8)6
Avg EPS beat(8)-4.36%
EPS beat(12)9
Avg EPS beat(12)-0.38%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)30.77%
PT rev (3m)30.77%
EPS NQ rev (1m)-0.36%
EPS NQ rev (3m)-0.36%
EPS NY rev (1m)0.55%
EPS NY rev (3m)-1.79%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)15.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 344.04
P/FCF N/A
P/OCF N/A
P/B 1.48
P/tB 1.49
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.63
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.01
BVpS1.49
TBVpS1.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -93.12%
ROE -105.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-12.96%
ROA(5y)-19.12%
ROE(3y)-13.36%
ROE(5y)-19.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.66%
Cap/Sales 8.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.57
Quick Ratio 9.57
Altman-Z 4.66
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)123.88%
Cap/Depr(5y)1424.33%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
EPS Next Y-547.4%
EPS Next 2Y-36.16%
EPS Next 3Y-14.85%
EPS Next 5Y16.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.14%
OCF growth 3YN/A
OCF growth 5YN/A